Aytu BioPharma Announces Appointment of Vivian Liu to the Company’s Board of Directors
ENGLEWOOD, CO /ACCESSWIRE/June 29, 2022/ Aytu BioPharma, Inc. (NASDAQ: AYTU), a pharmaceutical company focused on developing and commercializing novel therapies, today announced the appointment of Vivian Liu to the Company’s Board of Directors, effective July 1, 2022 Ms. Liu will serve as an independent director advisor and member of the Nominating and Corporate Governance Committee.
“I am delighted to welcome Vivian to Aytu’s Board of Directors as we continue to transform the business and focus on our key growth drivers, which are growing our business and building a valuable therapeutic pipeline focused on complex and pediatric rare diseases,” said Josh. Disbrow, CEO of Aytu BioPharma. “Vivian’s broad skill set and deep expertise in clinical and business development, as well as her significant experience building and leading emerging biotech companies, will serve the company well. Her knowledge of business development globally will help us evolve as we aim to deliver long-term shareholder value. I sincerely appreciate Vivian joining our Board of Directors at this important time in the company’s history. company.”
Vivian Liu commented, “I am delighted to join Aytu’s Board of Directors and look forward to assisting the management team as the company continues to progress on its strategic plans. As an executive and entrepreneur with many years in biotechnology and pharmaceuticals, I can appreciate the challenges and opportunities that lie ahead and I am ready to help lead Aytu as the company continues to grow.”
Vivian Liu is currently the General Affairs Manager of PREMIA Holdings (HK) Limited, a clinical genomic oncology database developer and service provider to pharmaceutical companies seeking to conduct clinical trials throughout Asia. Prior to joining PREMIA, Vivian held various positions, including as a member of the Board of Directors and President, Chief Executive Officer and Chief Financial Officer of Innovus Pharmaceuticals, Inc., a publicly traded consumer healthcare company acquired by Aytu BioPharma in February 2020. Prior to Innovus, she served as President and CEO of FasTrack Pharmaceuticals, Inc.
Vivian is currently an Independent Board Member and Chair of the Audit Committee of ThermoGenesis Holdings Inc., a publicly traded cell therapy company. From 2017 to 2018, she served as Chief Operating Officer and a member of the Board of Directors of the successor company to ThermoGenesis, Cesca Therapeutics, Inc. Previously, Vivian served as Managing Director of OxOnc Services Company, a development company in oncology, and prior to that, Ms. Liu co-founded and served as President, CEO and Board Director of NexMed, Inc., a drug development company which was later renamed Apricus BioSciences. Prior to her appointment as President of NexMed, Ms. Liu held several leadership positions, including as Executive Vice President, Chief Operating Officer, Chief Financial Officer and Vice President of Corporate Affairs. Ms. Liu holds an MPA from the University of Southern California and a BA from the University of California, Berkeley.
About Aytu BioPharma, Inc.
Aytu BioPharma is a pharmaceutical company with a portfolio of commercial prescription therapeutics and consumer health products, as well as a growing therapeutic pipeline focused on the treatment of rare pediatric disorders. The Company’s prescription products include Adzenys XR-ODT® (amphetamine) extended-release orally disintegrating tablets (see complete prescribing information, including boxed WARNING) and Cotempla XR-ODT® extended-release orally disintegrating tablets. ODT® (methylphenidate) (see full prescribing information, including boxed warning) for the treatment of attention deficit hyperactivity disorder (ADHD), as well as Karbinal® ER (carbinoxamine maleate), an antihistamine suspension with extended release containing carbinoxamine indicated to treat many allergic conditions, and Poly-Vi-Flor® and Tri-Vi-Flor®, two complementary lines of fluoride-based prescription vitamins in various formulations for infants and children with fluoride deficiency. Aytu is also building a therapeutic pipeline, which includes AR101 (enzastaurine), a PKCβ inhibitor in development for the treatment of Vascular Ehlers-Danlos Syndrome (VEDS). VEDS is a rare genetic disease usually diagnosed in childhood, resulting in high morbidity and a significantly shortened lifespan, and for which there is currently no approved treatment. AR101 has received Orphan Drug Designation and Fast Track Designation from the United States Food and Drug Administration and has received Orphan Drug Designation from the European Commission. Aytu is also researching and advancing the development of the Healight Ultraviolet A (UVA) Endotracheal Catheter, a patented investigational medical device with potential application in the treatment of severe and difficult-to-treat respiratory infections. To learn more, visit aytubio.com.
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, or the Exchange Act. All statements other than statements of historical facts contained in this press release are forward-looking statements. Forward-looking statements are generally written in the future tense and/or are preceded by words such as “may”, “shall”, “should”, “forecast”, “could”, “”expect” ”suggest” ” believe” ”estimate” ”continue” ”anticipate” ”intend” ”plan” or similar words, or negatives of these terms or other variations of these terms or of comparable terminology. Forward-looking statements, including, but not limited to, statements regarding financial results and statements set forth in this press release. These statements are only predictions and are subject to risks and uncertainties that could cause actual events or results to differ materially. These risks and uncertainties include, among others: the ability to attract and retain key members of the management team, the future growth potential of our business portfolio, start dates, durations and completion dates expected, as well as the potential safety and efficacy of our AR101 and Lumière product candidates. We also refer you to the risks described in the “Risk Factors” section of Aytu’s annual and quarterly reports on Forms 10-K and 10-Q and in other reports and documents filed with the Securities and Exchange Commission.
Mark Oki, Chief Financial Officer
Aytu BioPharma, Inc.
THE SOURCE: Aytu BioPharma, Inc.
See the source version on accesswire.com: